Phibro(US:PAHC)2024-05-09 19:52Financial Performance - Q3 FY24 (Consolidated) - Total consolidated net sales increased by 7% year-over-year, from $245.7 million to $263.2 million[24] - Adjusted EBITDA increased by 9% year-over-year, from $27.4 million to $29.7 million[24] - Net income decreased by 16% year-over-year, from $10.0 million to $8.4 million[24] - Adjusted net income increased by 9% year-over-year, from $11.6 million to $12.7 million[24] Financial Performance - Q3 FY24 (Animal Health) - Animal Health net sales increased by 10% year-over-year, from $164.4 million to $181.3 million[27] - Vaccines sales increased by 26% year-over-year[7, 27] - MFAs (Medicated Feed Additives) and other sales increased by 16% year-over-year[7, 27] - Nutritional specialties sales decreased by 11% year-over-year[7, 27] - Animal Health adjusted EBITDA increased by 7% year-over-year, from $34.2 million to $36.5 million[27] Acquisition and Guidance - The company is set to acquire Zoetis' MFA and certain water-soluble products business for $350 million, subject to adjustments[7] - The company affirms fiscal year 2024 guidance with net sales of $980 million to $1.020 billion and adjusted EBITDA of $106 million to $112 million[7]